Literature DB >> 7059439

Effect of rifampicin on metoprolol and antipyrine kinetics.

P N Bennett, V A John, V B Whitmarsh.   

Abstract

1 Effects of rifampicin on the pharmacokinetics of single oral doses of metoprolol and antipyrine are reported. 2 Rifampicin, administered daily for 15 days, reduced the area under the plasma concentration-time curve (AUC) of metoprolol but the rate constant for elimination (beta) of metoprolol from plasma did not alter significantly. 3 Administration of rifampicin for 13 days reduced AUC and increased beta of antipyrine. Thirteen days after discontinuing rifampicin. AUC and beta of antipyrine remained significantly different from the initial values. 4 Some loss of beta-adrenoceptor blockade should be anticipated if rifampicin is administered to patients who are receiving metoprolol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059439      PMCID: PMC1402102          DOI: 10.1111/j.1365-2125.1982.tb01390.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

3.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

4.  Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.

Authors:  C G Regårdh; G Johnsson; L Jordö; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

5.  Metabolism of metoprolol-(3-h) in man, the dog and the rat.

Authors:  K O Borg; E Carlsson; K J Hoffmann; T E Jönsson; H Thorin; B Wallin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

6.  Dose-dependent enzyme induction.

Authors:  A Breckenridge; M L Orme; L Davies; S S Thorgeirsson; D S Davies
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

7.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

8.  Rapid gas-liquid chromatographic estimation of antipyrine in plasma.

Authors:  L F Prescott; K K Adjepon-Yamoah; E Roberts
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

9.  Metabolism of metoprolol in the rat in vitro and in vivo.

Authors:  A Arfwidsson; K O Borg; K J Hoffmann; I Skånberg
Journal:  Xenobiotica       Date:  1976-11       Impact factor: 1.908

10.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

View more
  22 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Pharmacokinetics of antipyrine in epileptic patients.

Authors:  E M Rimmer; P A Routledge; L M Tsanaclis; A Richens
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

4.  Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.

Authors:  D Vital Durand; C Hampden; A R Boobis; B K Park; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

5.  Enzyme induction and beta-adrenergic receptor blocking drugs.

Authors:  R A Branch; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

6.  Drug interactions and beta blockers.

Authors:  L Beeley
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-17

7.  Pharmacokinetic interaction between rifampin and zidovudine.

Authors:  D M Burger; P L Meenhorst; C H Koks; J H Beijnen
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.

Authors:  S M Borcherding; T L Bastian; T H Self; N Abou-Shala; B W LeDuc; R L Lalonde
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.